Titre : | Extended-release methylphenidate for treatment of amphetamine/methamphetamine dependence: a randomized, double-blind, placebo-controlled trial (2013) |
Auteurs : | S. W. MILES ; J. SHERIDAN ; B. RUSSELL ; R. KYDD ; A. WHEELER ; C. WALTERS ; G. GAMBLE ; P. HARDLEY ; M. JENSEN ; K. KUOPPASALMI ; P. TUOMOLA ; J. FÖHR ; O. KUIKANMAKI ; H. VORMA ; R. K. SALOKANGAS ; A. MIKKONEN ; M. KALLIO ; J. KAUHANEN ; V. KIVINIEMI ; J. TIIHONEN |
Type de document : | Article : Périodique |
Dans : | Addiction (Vol.108, n°7, July 2013) |
Article en page(s) : | 1279-1286 |
Langues: | Anglais |
Discipline : | TRA (Traitement et prise en charge / Treatment and care) |
Mots-clés : |
Thésaurus mots-clés AMPHETAMINES ; METHAMPHETAMINE ; METHYLPHENIDATE ; SUBSTITUTION ; ETUDE RANDOMISEE ; EFFICACITE ; EPIDEMIOLOGIE DESCRIPTIVEThésaurus géographique FINLANDE ; NOUVELLE ZELANDE |
Résumé : |
Aims To assess the efficacy of methylphenidate as a substitution therapy for amphetamine/methamphetamine dependence in Finland and New Zealand. Design Parallel-group, double-blind, randomized placebo-controlled trial. Setting Out-patient care. Participants Amphetamine-/methamphetamine-dependent, aged 16-65 years. Measurements The primary outcome measure was presence/absence of amphetamine/methamphetamine in urine samples collected twice weekly. Secondary measures included treatment adherence, alterations in craving scores and self-reported use. Primary analysis was by intention-to-treat (ITT). The study drug, methylphenidate (as Concerta®), was up-titrated over 2 weeks to a maximum dose of 54 mg daily and continued for a further 20 weeks. Doses were given under daily supervision at the clinics. Findings Seventy-nine participants were randomized (40 methylphenidate; 39 placebo); 76 received allocated treatment and 27 completed the trial. ITT analysis (n = 78) showed no statistically significant difference in the percentage of positive urines between the methylphenidate and placebo arms (odds ratio: 0.95, 95% confidence interval: 0.83-1.08). However, there was a significant difference (P
HIGHLIGHTS: Methylphenidate may improve retention of amphetamine/methamphetamine users in substance misuse treatment but any effect on substance misuse remains unproven. |
Domaine : | Drogues illicites / Illicit drugs |
Refs biblio. : | 32 |
Affiliation : | University of Auckland, Auckland, New Zealand |
Cote : | Abonnement |
Lien : | http://dx.doi.org/10.1111/add.12109 |
Accueil